Limits...
Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).

De Santis R, Anastasi AM, D'Alessio V, Pelliccia A, Albertoni C, Rosi A, Leoni B, Lindstedt R, Petronzelli F, Dani M, Verdoliva A, Ippolito A, Campanile N, Manfredi V, Esposito A, Cassani G, Chinol M, Paganelli G, Carminati P - Br. J. Cancer (2003)

Bottom Line: The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of an additional, nonfunctional light chain.ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic epitope of BC4.It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry.

View Article: PubMed Central - PubMed

Affiliation: Immunology Department, Sigma Tau SpA R&D, Pomezia, Rome, Italy. rita.desantis@sigma-tau.it

ABSTRACT
The Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT) method is based on intravenous, sequential administration of a biotinylated antibody, avidin/streptavidin and (90)Y-labelled biotin. The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of an additional, nonfunctional light chain. In order to solve this problem, the new cST2146 hybridoma clone was generated. The monoclonal antibody ST2146, produced by this hybridoma, having the same specificity as BC4 but lacking the nonfunctional light chain, was characterised. ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic epitope of BC4. It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry. Biodistribution studies of biotinylated ST2146 and three other monoclonal antitenascin antibodies showed for ST2146 the highest and more specific tumour localisation in HT29-grafted nude mice. On the overall, ST2146 appears to be a good alternative to BC4 for further clinical development of PAGRIT.

Show MeSH

Related in: MedlinePlus

Schematic representation of human tenascin-C, pTn28 and A–D recombinant fragments and strategy to generate a BC4-like antibody.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376359&req=5

fig1: Schematic representation of human tenascin-C, pTn28 and A–D recombinant fragments and strategy to generate a BC4-like antibody.

Mentions: In order to generate a BC4-like monoclonal antibody, hybridomas were produced from mice immunised with the recombinant pTn28 phage lysate encoding the EGF-like repeats of human tenascin previously shown to contain the BC4 antigenic epitope. Figure 1Figure 1


Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).

De Santis R, Anastasi AM, D'Alessio V, Pelliccia A, Albertoni C, Rosi A, Leoni B, Lindstedt R, Petronzelli F, Dani M, Verdoliva A, Ippolito A, Campanile N, Manfredi V, Esposito A, Cassani G, Chinol M, Paganelli G, Carminati P - Br. J. Cancer (2003)

Schematic representation of human tenascin-C, pTn28 and A–D recombinant fragments and strategy to generate a BC4-like antibody.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376359&req=5

fig1: Schematic representation of human tenascin-C, pTn28 and A–D recombinant fragments and strategy to generate a BC4-like antibody.
Mentions: In order to generate a BC4-like monoclonal antibody, hybridomas were produced from mice immunised with the recombinant pTn28 phage lysate encoding the EGF-like repeats of human tenascin previously shown to contain the BC4 antigenic epitope. Figure 1Figure 1

Bottom Line: The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of an additional, nonfunctional light chain.ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic epitope of BC4.It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry.

View Article: PubMed Central - PubMed

Affiliation: Immunology Department, Sigma Tau SpA R&D, Pomezia, Rome, Italy. rita.desantis@sigma-tau.it

ABSTRACT
The Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT) method is based on intravenous, sequential administration of a biotinylated antibody, avidin/streptavidin and (90)Y-labelled biotin. The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of an additional, nonfunctional light chain. In order to solve this problem, the new cST2146 hybridoma clone was generated. The monoclonal antibody ST2146, produced by this hybridoma, having the same specificity as BC4 but lacking the nonfunctional light chain, was characterised. ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic epitope of BC4. It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry. Biodistribution studies of biotinylated ST2146 and three other monoclonal antitenascin antibodies showed for ST2146 the highest and more specific tumour localisation in HT29-grafted nude mice. On the overall, ST2146 appears to be a good alternative to BC4 for further clinical development of PAGRIT.

Show MeSH
Related in: MedlinePlus